

Practitioner's Docket No. MBIO99-030CP1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Barnes, Thomas M., et al.
Application No.: 09/578,063 Group No.: 1646
Filed: May 24, 2000 Examiner: Dong Jiang
For: NOVEL GENES ENCODING PROTEINS HAVING DIAGNOSTIC,
PREVENTIVE, THERAPEUTIC, AND OTHER USES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

1. Transmitted herewith for this application is/are:
- This Transmittal Letter (2 pages);
 - Response to Office Action dated February 13, 2003 (7 pages), including Appendix A (2 pages) and Appendix B (4 pages);
 - Deposit Declaration (2 pages); and
 - Copies of the relevant portions of references cited herein (pages 191 and 192 of Gurr, M.I., et al. (1991) *Lipid Biochemistry, Fourth Edition*; and page 562 of Merriam-Webster's Medical Desk Dictionary (1st ed. 1996))(3 pages total)

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Signature

Paul J. Paglierani

(type or print name of person certifying)

Date: May 13, 2003

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MBIO99-030CP1M

Application No. 09/578,063

FEE DEFICIENCY

3. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

May 13, 2003

MILLENNTIUM PHARMACEUTICALS, INC.

By: 

Paul J. Paglierani
Registration No. 52,498
75 Sidney Street
Cambridge, MA 02139
Telephone - 617-761-6865
Facsimile - 617-551-8820

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Practitioner's Docket No. MBIO99-030CP1M

PATENT

FAX RECEIVED

Certificate of Transmission under 37 CFR 1.8

MAY 14 2003

GROUP 1600

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on May 13, 2003

Signature

Paul J. Paglerant

Typed or printed name of person signing Certificate

OFFICIAL

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Transmittal Letter	(2 pages);
Response to Office Action dated February 13, 2003 (7 pages), including	
Appendix A (2 pages) and Appendix B (4 pages)	(13 pages);
Deposit Declaration	(2 pages); and
Copies of the relevant portions of references cited herein	(3 pages)
 Total	 (21 pages-including fax cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.